43,996 Shares in Codexis, Inc. (NASDAQ:CDXS) Purchased by Jackson Square Capital LLC

Jackson Square Capital LLC bought a new position in shares of Codexis, Inc. (NASDAQ:CDXS) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 43,996 shares of the biotechnology company’s stock, valued at approximately $210,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Private Advisor Group LLC lifted its holdings in shares of Codexis by 1.3% during the third quarter. Private Advisor Group LLC now owns 278,699 shares of the biotechnology company’s stock worth $858,000 after purchasing an additional 3,458 shares during the period. Rhumbline Advisers lifted its holdings in Codexis by 3.8% in the second quarter. Rhumbline Advisers now owns 108,594 shares of the biotechnology company’s stock valued at $337,000 after acquiring an additional 4,017 shares during the period. Perkins Capital Management Inc. lifted its holdings in Codexis by 2.8% in the third quarter. Perkins Capital Management Inc. now owns 164,100 shares of the biotechnology company’s stock valued at $505,000 after acquiring an additional 4,500 shares during the period. Algert Global LLC lifted its holdings in Codexis by 17.1% in the second quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock valued at $129,000 after acquiring an additional 6,069 shares during the period. Finally, Empire Financial Management Company LLC lifted its holdings in Codexis by 4.7% in the third quarter. Empire Financial Management Company LLC now owns 222,952 shares of the biotechnology company’s stock valued at $687,000 after acquiring an additional 10,000 shares during the period. Institutional investors and hedge funds own 78.54% of the company’s stock.

Codexis Trading Up 1.6 %

Shares of CDXS stock opened at $5.00 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. The company has a market cap of $406.90 million, a price-to-earnings ratio of -5.75 and a beta of 2.13. The stock has a 50 day simple moving average of $4.80 and a 200-day simple moving average of $3.73. Codexis, Inc. has a 1-year low of $2.53 and a 1-year high of $6.08.

Codexis (NASDAQ:CDXS) last announced its earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The business had revenue of $12.83 million for the quarter, compared to analyst estimates of $11.64 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. During the same period in the previous year, the company earned ($0.26) earnings per share. On average, equities research analysts expect that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CDXS. Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price target on shares of Codexis in a report on Friday, November 22nd. Benchmark reissued a “hold” rating on shares of Codexis in a report on Monday, November 4th.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.